SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is currently trending with immense community excitement following the landmark approval of its Anktiva therapy for lung and bladder cancer in Saudi Arabia, signaling a potential paradigm shift in oncology. This development, amplified by recent executive discussions, has ignited investor focus on the innovative, non-chemotherapy treatment and fuels widespread speculation of a significant market move amidst high short interest and growing calls for faster US regulatory action.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point ahead of its upcoming earnings report and the ongoing complexities surrounding a potential Warner Bros. Discovery acquisition. Community sentiment is deeply split, with some anticipating a significant rebound from perceived oversold levels, while others caution about lingering valuation concerns and deal-related risks. The recent disclosure of a prominent figure acquiring bonds in both companies further fuels the debate over its short-term trajectory.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is currently trending due to its exceptionally active and dedicated community, which is relentlessly building a permissionless brand with numerous real-world products and initiatives. Community members express strong bullish conviction, emphasizing long-term growth and the project's consistent expansion of its ecosystem across multiple blockchain platforms like ETH, SOL, and BASE.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is experiencing significant market volatility, with community discussion centered on recent sharp declines despite a new analyst upgrade to $835. Bulls argue the stock's AI-powered AXON platform and strong fundamentals make current dips a buying opportunity, often attributing the fall to market manipulation or recurring allegations of fraudulent practices. Conversely, bears highlight the stock's valuation and sector-wide weakness, questioning its stability and anticipating further downside.

Avio SpA provides aerospace propulsion systems, engine modules and components. It specializes in equipment, stage assembly, composite containers and structures, SRM thermal protections, structural elements, SRM nozzle, functional tests, cryogenic propulsion, upper-stage storable propulsion, feeding systems, and spacecraft propulsion. The company was founded in 1908 and is headquartered in Colleferro, Italy.

Avio S.p.A - ADR

Avio American Depositary Shares

Avio American Depositary Shares (AVVSY) is trending due to recent significant launch contract wins and its strategic expansion into the U.S. market with a planned manufacturing facility. The community is actively discussing its strong year-over-year growth and robust fundamentals, perceiving it as an undervalued European pure-play space provider compared to its U.S. peers.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as geopolitical tensions escalate, notably with recent US actions in Venezuela and renewed tariff discussions concerning the EU over Greenland. The community is actively debating its potential as a volatility hedge amidst broader market stability concerns, with many anticipating a significant spike despite its inherent decay characteristics.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is a focal point of market discussion, driven by heightened geopolitical interest in Greenland's critical mineral resources amidst ongoing international negotiations and potential tariffs. The community is actively anticipating a forthcoming corporate business update, expecting positive developments regarding the Tanbreez project's progress and its strategic partnerships, which already account for 100% of its rare earth concentrate production.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network ($ROSE) is trending amidst community excitement over its strategic pivot and rebranding to 'Rose AI', emphasizing privacy-enabled decentralized applications. This renewed focus is bolstered by developments like the ROFL Mainnet launch and high-profile collaborations with entities such as Google and BMW. Investors are actively discussing ROSE's potential as an undervalued gem, highlighting its foundational role in confidential computing and secure data solutions at the intersection of Web3 and the rapidly expanding AI sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant upward momentum due to an unprecedented memory chip shortage, fueled by explosive AI demand for high-bandwidth memory (HBM). Recent catalysts, including a major insider stock purchase and the groundbreaking of new manufacturing facilities, reinforce bullish sentiment, with the community actively debating its 'unstoppable momentum' and 'ridiculously cheap' valuation versus concerns about being 'overextended'.

Direxion Shares ETF Trust - Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily 20+ Year Treasury Bull 3X Shares

TMF is trending as investors intensely debate the Federal Reserve's path for interest rates, with many anticipating upcoming cuts driven by mounting recessionary signals like rising layoffs and a weakening economy. While some community members are aggressively bullish, expecting a significant rally in long-dated Treasuries, an equally vocal contingent sees bonds as an easy short, believing yields will remain elevated or climb further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stephens Investment Management Group LLC Purchases Shares of 1,599,668 Travere Therapeutics, Inc. $TVTX

Stephens Investment Management Group LLC purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the third quarter, according to its most recent disclosure...

Mirum Stock Rises 7% in a Week: Here's What You Should Know

MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook,  key pipeline goals and business updates.

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information...

Equities Analysts Issue Forecasts for TVTX FY2030 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Travere Therapeutics in a report issued on Wednesday, January 14th. HC...

TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA

Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.

<ul class="summary-bullets"><li>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit.</li><li>The company submitted responses and the agency determined that the responses constitute a major amendment to the application.&nbsp;</li><li>The FDA is now expected to decide on the application by April 13, 2026.</li></ul>Shares of Travere Therapeutics, Inc., (TVTX) traded 19% lower on Tuesday after the company announced that U.S. Food and Drug Administration (FDA) has extended the review timeline for its application seeking approval of Filspari in focal segmental glomerulosclerosis.The FDA is now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-FDA-Extends-Review-of-sNDA-for-FILSPARI-sparsentan-in-FSGS/default.aspx">expected</a> to decide on the application by April 13, 2026. The agency was initially expected to rule on the application by Jan. 13.<h2 class="st-heading-2">Why The Delay?</h2>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline, the company said. The agency requested no additional information on the safety or manufacturing of Filspari, it added.According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. FSGS is a kidney disease causing sclerosis, or scarring in some filters of the kidneys, leading to protein leakage, swelling, and potentially kidney failure.CEO Eric Dube said that the company remains committed to working with the FDA during the extension period and making preparations for a potential commercial launch.Filspari is also approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease where deposits of the immunoglobulin A (IgA) antibody build up in the kidney's filters, causing inflammation, scarring, and damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the FDA would eventually reject the drug.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/641686497</stembedurl>Another opined that the FDA wouldn’t have extended the review timeline if it was planning on a rejection.<stembedurl>https://www.stocktwits.com/apux/message/641686139</stembedurl><a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> has gained 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 

Equity

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 


Travere Therapeutics, Sony And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul class="summary-bullets"><li>Travere said its responses are currently under agency review.</li><li>FDA’s PDUFA target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis is January 13.</li><li>The company expects U.S. net product sales of about $127 million in Q4 and about $410 million for the full year 2025.</li></ul>Shares of Travere Therapeutics Inc.&nbsp;(TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.Travere said its responses are currently under agency review. Filspari is a treatment for adults with primary immunoglobulin A nephropathy, a progressive kidney disease that can ultimately lead to kidney failure.FDA’s PDUFA (Prescription Drug User Fee Act) target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis (FSGS) is January 13. A PDUFA date is the FDA's target date to make a decision on a drug application. If approved, Filspari would be the first treatment for FSGS, and the company says it is well-positioned for a commercial launch.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp premarket decline, retail sentiment on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day back, accompanied by ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/TVTX_jpg_74da780cfd.webp" alt="TVTX.jpg">One user said that the FDA’s request is ‘very common’.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/641602359</stembedurl>However, one bearish user was skeptical about the timelines.<stembedurl>https://stocktwits.com/Aawilliam2003/message/641609384</stembedurl><h2 class="st-heading-2">2026 Outlook</h2>Travere Therapeutics provided an update on its sales outlook for the fourth quarter and full year 2025. The company expects U.S. net product sales of about $127 million in the fourth quarter (Q4) and about $410 million for the full year, based on preliminary and unaudited results. Travere ended 2025 with around $323 million in cash, cash equivalents, and marketable securities.Clinically, the company plans to advance clinical evidence supporting FILSPARI as a foundational treatment for IgA nephropathy, also known as Berger's disease, a chronic kidney ailment. Its partner, Chugai Pharmaceutical, is expected to submit a New Drug Application (NDA) for Sparsentan in Japan next year.Meanwhile, the company is on track to restart Phase 3 HARMONY Study of Pegtibatinase in classical homocystinuria (HCU), a genetic metabolic disorder, in the first quarter of 2026 following manufacturing process improvements.The stock has seen significant buying interest over the past year, gaining nearly 90%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-nvts-stock-gaining-retail-attention-ai-power-play/cmUXcZPR44k">NVTS Stock Draws Retail Interest On AI Data Center Power Play</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did TVTX Stock Crash 30% In Pre-Market Today?

Shares of Travere Therapeutics Inc. (TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.

The U.S. Food and Drug Administration recently requested additional information to assess Filspari’s clinical benefit.

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.2% - Here's What Happened

Travere Therapeutics (NASDAQ:TVTX) Shares Down 6.2% - Time to Sell...

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Current Price	$27.87
Prev Close	$28.40
Open	$28.50
Dividend Yield	0.00%
50-Day Moving Average	$35.00
Beta	1.42
Avg. Volume	1.75M
PE Ratio	-25.70

52-Week High	$42.13
52-Week Low	$12.91
Market Capitalization	$2.49B
EPS (Annual)	-$4.08
Price to Book	33.89
Revenue Per Employee	$605,649.35
Enterprise Value/EBITDA	N/A

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TVTX News

TVTXTravere Therapeutics Inc